

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Ivabradine hydrochloride

March 17, 2026

Therapeutic category

HCN channel blocker

Non-proprietary name

Ivabradine hydrochloride

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
 This English version is intended to be a reference material to provide convenience for users.
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current			Revision		
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) 2.7 Patients receiving the following drugs: Preparations containing ritonavir, josamycin, itraconazole, clarithromycin, preparations containing cobicistat, voriconazole, ensitrelvir fumaric acid 10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following.)			2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) 2.7 Patients receiving the following drugs: Preparations containing ritonavir, josamycin, itraconazole, clarithromycin, preparations containing cobicistat, voriconazole, ensitrelvir fumaric acid, <u>ceritinib</u> 10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following.)		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Preparations containing ritonavir Josamycin Itraconazole Clarithromycin Preparations containing cobicistat Voriconazole Ensitrelvir fumaric acid	Excessive bradycardia may occur.	CYP3A-mediated metabolism of this drug is strongly inhibited, leading to an increase in the blood concentration of this drug.	Preparations containing ritonavir Josamycin Itraconazole Clarithromycin Preparations containing cobicistat Voriconazole Ensitrelvir fumaric acid <u>Ceritinib</u>	Excessive bradycardia may occur.	CYP3A-mediated metabolism of this drug is strongly inhibited, leading to an increase in the blood concentration of this drug.